Published in the European Heart Journal, this research tracked 15,668 Australian and American adults aged mostly 70 and over who had taken part in the original clinical trial published in 2018. While the initial study had found no cardiovascular benefits and a higher risk of major hemorrhage, the new trial extension followed participants for an additional 4.3 years, bringing the total median follow-up to 8.3 years.
Over this extended period, the researchers again found no evidence that aspirin use provided cardiovascular protection. Instead, they confirmed an elevated risk of major bleeding. Participants who had been randomized to receive aspirin in the original trial showed a 17 percent higher rate of adverse cardiovascular events compared with the placebo group during the post-trial phase. These results reinforce concerns that the drug may harm rather than help older adults when used for primary prevention.
To learn more about the dangers of aspirin, see this article on our website.
Trump Demands Definitive Answer Amid Ongoing Debate Over COVID-19 Vaccines
September 12, 2025Meta-Analysis Supports Vitamin D Supplements for Heart Health
September 12, 2025Taking Aspirin Daily Provides No Long-Term Prevention of Cardiovascular Events in Older Adults
News
Research from a Monash University-led team has confirmed 2018 research that found healthy older adults who took a low-dose of aspirin daily experienced a higher risk of a major hemorrhage without any overall cardiovascular benefit.
[Source: medicalxpress.com]
[Image source: Adobe Stock]
Comment
Published in the European Heart Journal, this research tracked 15,668 Australian and American adults aged mostly 70 and over who had taken part in the original clinical trial published in 2018. While the initial study had found no cardiovascular benefits and a higher risk of major hemorrhage, the new trial extension followed participants for an additional 4.3 years, bringing the total median follow-up to 8.3 years.
Over this extended period, the researchers again found no evidence that aspirin use provided cardiovascular protection. Instead, they confirmed an elevated risk of major bleeding. Participants who had been randomized to receive aspirin in the original trial showed a 17 percent higher rate of adverse cardiovascular events compared with the placebo group during the post-trial phase. These results reinforce concerns that the drug may harm rather than help older adults when used for primary prevention.
To learn more about the dangers of aspirin, see this article on our website.
Dr. Rath Health Foundation
Related posts
Slovakia to Challenge EU Deregulation of Gene Editing in Court
Read more